371 related articles for article (PubMed ID: 18482053)
21. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
[TBL] [Abstract][Full Text] [Related]
23. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
[TBL] [Abstract][Full Text] [Related]
24. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
[TBL] [Abstract][Full Text] [Related]
25. JAK2, the JAK2 V617F mutant and cytokine receptors.
Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
[TBL] [Abstract][Full Text] [Related]
26. Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.
Kraus M; Wang Y; Aleksandrowicz D; Bachman E; Szewczak AA; Walker D; Xu L; Bouthillette M; Childers KM; Dolinski B; Haidle AM; Kopinja J; Lee L; Lim J; Little KD; Ma Y; Mathur A; Mo JR; O'Hare E; Otte RD; Taoka BM; Wang W; Yin H; Zabierek AA; Zhang W; Zhao S; Zhu J; Young JR; Marshall CG
PLoS One; 2012; 7(5):e37207. PubMed ID: 22623993
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
Funakoshi-Tago M
Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321
[TBL] [Abstract][Full Text] [Related]
28. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
29. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
30. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
31. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
32. Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.
Swierczek SI; Yoon D; Bellanné-Chantelot C; Kim SJ; Saint-Martin C; Delhommeau F; Najman A; Prchal JT
Haematologica; 2011 May; 96(5):775-8. PubMed ID: 21273266
[TBL] [Abstract][Full Text] [Related]
33. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
35. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
[TBL] [Abstract][Full Text] [Related]
36. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Guerini V; Barbui V; Spinelli O; Salvi A; Dellacasa C; Carobbio A; Introna M; Barbui T; Golay J; Rambaldi A
Leukemia; 2008 Apr; 22(4):740-7. PubMed ID: 18079739
[TBL] [Abstract][Full Text] [Related]
37. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
38. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.
da Costa Reis Monte-Mór B; Plo I; da Cunha AF; Costa GG; de Albuquerque DM; Jedidi A; Villeval JL; Badaoui S; Lorand-Metze I; Pagnano KB; Saad ST; Vainchenker W; Costa FF
Leukemia; 2009 Jan; 23(1):144-52. PubMed ID: 18843287
[TBL] [Abstract][Full Text] [Related]
39. Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway.
Trung LQ; Espinoza JL; An DT; Viet NH; Shimoda K; Nakao S
Mol Nutr Food Res; 2015 Nov; 59(11):2143-54. PubMed ID: 26375873
[TBL] [Abstract][Full Text] [Related]
40. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]